69171-62-6

Basic information

• Product Name: Butanoicacid, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-
• Synonyms: Butanoicacid, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-;4-[(1,1-Dimethylethyl)dimethylsilyl]oxy]butanoic acid;4-[(tert-Butyldimethylsilanyl)oxy]butyric acid
• CAS NO: 69171-62-6
• Molecular Formula: C₁₀H₂₂O₃Si
• Molecular Weight: 218.36538
• Mol File: 69171-62-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 273.1 °C at 760 mmHg
• Flash Point: 119 °C
• Appearance: /
• Density: 0.947 g/cm³
• Vapor Pressure: 0.00162mmHg at 25°C
• Refractive Index: 1.437
• CAS DataBase Reference: Butanoicacid, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoicacid, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-(69171-62-6)
• EPA Substance Registry System: Butanoicacid, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-(69171-62-6)

Safety Data

• Hazardous Substances Data: 69171-62-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H22O3Si/c1-10(2,3)14(4,5)13-8-6-7-9(11)12/h6-8H2,1-5H3,(H,11,12)

Upstream product

• 591-81-1 4-hydroxybutanoic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 88245-09-4 C₂₅H₄₂O₆Si 
• 121846-32-0 4-Hydroxy-butyric acid (3E,5E,7E)-7-methyl-9-oxo-3-[(E)-2-(2,6,6-trimethyl-cyclohex-1-enyl)-vinyl]-nona-3,5,7-trienyl ester 
• 658057-64-8 4-(tert-butyl(dimethyl)silanyloxy)butyric acid phenyl ester 
• 658057-65-9 4-(tert-butyl(dimethyl)silanyloxy)-2-((6-chloropyridin-3-yl)methyl)butyric acid phenyl ester 
• 914289-10-4 4-(tert-butyldimethylsilanyloxy) butyric acid (7R,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine-8-yl ester 
• 936731-49-6 (S)-4-benzyl-3-[4-(tert-butyldimethylsilanyloxy)butanoyl]oxazolidin-2-one 
• 1355510-17-6 (S)-5-phenylpent-1-en-3-yl 4-(tert-butyldimethylsilyloxy)butanoate 
• 1447956-92-4 C₂₇H₄₄N₄O₃SSi 

Relevant articles and documents

A hydrophilic medicament phospholipid compound, its pharmaceutical composition and application

The invention discloses a phospholipid compound of hydrophilic drugs as well as a pharmaceutical composition and application of the phospholipid compound. The pharmaceutical composition of the phospholipid compound of the hydrophilic drugs or a combined pharmaceutical composition of the phospholipid compound of the hydrophilic drugs and a pharmacologically acceptable carrier; and the pharmaceutical composition is in the form of a liquid preparation, a solid preparation, a semisolid preparation, a capsule, granules, a gel or an injection. The pharmaceutical composition is in the form of liposome nanoparticles prepared from the phospholipid compound of the hydrophilic drugs or the phospholipid compound of the hydrophilic drugs and adjuvants, and the pharmaceutical composition is 10-1000nm in grain size. The phospholipid compound of the hydrophilic drugs and the liposome nanoparticles thereof can serve as a liquid preparation, a solid preparation, a semisolid preparation, a sterilized preparation and a sterile preparation; and the phospholipid compound of the hydrophilic drugs and the liposome nanoparticles thereof are low in toxicity, and are applicable to the efficient treatment of various tumors and the like.